Early diabetic nephropathy in type 1 diabetes: New insights

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 4, 2014, Pages 279-286

  Bjornstad, Petter ^a   Cherney, David ^b   Maahs, David M ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

early diabetic nephropathy; glomerular filtration rate; insulin sensitivity; serum uric acid; sodium glucose cotransporter 2

Indexed keywords

CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIAGNOSTIC PROCEDURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NEPHROLOGY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; EARLY DIAGNOSIS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COPEPTIN; GLYCOPEPTIDE; SODIUM GLUCOSE COTRANSPORTER 2; URIC ACID;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; GLYCOPEPTIDES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SODIUM-GLUCOSE TRANSPORTER 2; URIC ACID;

EID: 84903754875     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000074     Document Type: Review

References (89)

1. Maahs DM, Rewers M. Mortality and renal disease in type 1 diabetes mellitus-progress maDe, more to be done [editorial]. J Clin Endocrinol Metab 2006; 91:3757-3759. (Pubitemid 44536838)
2. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh EpiDemiology of Diabetes Complicatio ns Study. Diabetologia 2010; 53:2312-2319.
3. Collins AJ, Foley RN, Chavers B, et al. ?United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012; 59 (1 Suppl 1):A7,e1-A7,e420.
4. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia 2012; 55:2301-230 6. An important review of the outlook of diabetic nephropathy in T1D.
5. Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985; 78:785-794. (Pubitemid 15008233)
6. Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011; 57 (1 Suppl 1):A8,e1-A8,e526.
7. . Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin DepenDent diabetes mellitus. Br Med J (Clin Res Ed) 1987; 294:1651-1654. (Pubitemid 17088017)
8. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh EpiDemiology of Diabetes Complications Study. Diabetes Care 200 3; 26:1374-1379. (Pubitemid 36929165)
9. Maahs DM, Jalal D, Chonchol M, et al. Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: the CACTI study. Diabetes Care 2013; 36:2607-2614.
10. International evaluation of cause-specific mortality and IDDM. Diabetes EpiDemiology Research International Mortality Study Group. Diabetes Care 1991; 14:55-60.
11. Daniels M, DuBose SN, Maahs DM, et al. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D exchange clinic registry. Diabetes Care 2013; 36:2639-2645.
12. Mauer M, Drummond K. The early natural history of nephropathy in type 1 diabetes: I. Study Design and baseline characteristics of the study participants. Diabetes 2002; 51: 1572-1579. (Pubitemid 34826627)
13. Osterby R, Gall MA, Schmitz A, et al. Glomerular structure and function in proteinuric type 2 (noninsulin-DepenDent) diabetic patients. Diabetologia 1993; 36:1064-1070. (Pubitemid 23288777)
14. Lewis EJ, Hunsicker LG, Bain RP, RohDe RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462. (Pubitemid 23335891)
15. Doria A, Niewczas MA, Fiorina P. Can existing drugs approved for other indications retard renal function Decline in patients with type 1 diabetes and nephropathy? Semin Nephrol 2012; 32:437-444.
16. Pambianco G. Costacou T. Ellis D. et al. The 30-year natural history of type 1 diabetes complications: The Pittsburgh EpiDemiology of Diabetes Complications Study experience Diabetes 2006 55 1463-1469.
17. Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh EpiDemiology of Diabetes Complications Study experience. Diabetes 2006; 55:1463-1469.
18. Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clin ical guiDelines. Diabetes care 2013; 36:2035-2037.
19. Mauer M,Zinman B,Gardiner R,et al,Renal and retinal effects of enalapril and losartan in type 1 diabetes,N Engl J Med, 2009; 361,40-51.
20. Mann JF, AnDerson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hyperte ns 2013; 31:414-421. Demonstrates harm with dual RAAS blockaDe.
21. Cherney DZ, Konvalinka A, Zinman B, et al. Effect of protein kinase Cb inhibition on renal hemodynamic function and urinary biomark ers in humans with type 1 diabetes: a pilot study. Diabetes Care 2009; 32:91-93.
22. Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2:631-636.
23. De Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492-2503.
24. Maahs DM. Cardiovascular disease (CVD) limbo: how soon and low should we go to prevent CVD in diabetes? Diabetes Technol Ther 2012; 14:449-452.
25. Jala l DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the Development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial T ranspl 2010; 25:1865- 1869.
26. Maahs DM, Caramori L, Cherney DZ, et al. Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) Allopurinol Study. Curr Diab Rep 2013; 13:550-559. A clinical trial with allopurinol to prevent early diabetic nephropathy in T1D.
27. Rodrigues TC, Maahs DM, Johnson RJ, et al. Serum uric acid predicts pro gression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 2010; 33:2471-2473.
28. Bjornstad P, Snell-Bergeon JK, Rewers M, et al. Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes. Diabetes Care 2013; 36:3678-3683.
29. Specht BJ, Wadwa RP, Snell-Bergeon JK, et al. Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes. J Pediatr 2013; 162:297-301.
30. Cherney DZ, Perkins BA, Soleymanlou N , et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587-597.
31. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have aDequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36:2508-2515.
32. Boertien WE, Riphagen IJ, Drion I, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with Declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013; 56:1680-1688.
33. Riphagen IJ, Boertien WE, Alkhalaf A, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with t ype 2 diabetes (ZODIAC-31). Diabetes Care 2013; 36:3201-3207.
34. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19:1283-1290.
35. Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61:3304-3313.
36. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51:1580-1587. (Pubitemid 34826628)
37. Magee GM, Bilous RW, Cardwell CR, et al. Is hyperfiltration associated with the future risk of Developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52:691-697.
38. Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164-176. (Pubitemid 40095801)
39. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285-2293. (Pubitemid 36638102)
40. Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal Decline preceDes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes c are 2014; 37:226-234.
41. Shlipak MG,Katz R,Kestenbaum B,et al,Rapid Decline of kidney function increases cardiovascular risk in the elDerly,J Am Soc Nephrol,2009,20,2625-2630.
42. Shlipak MG, Katz R, Kestenbaum B, et al. Rate of kidney function Decline in olDer adults: a comparison using creatinine and cystatin C. Am J Nephrol 2009; 30:171-178.
43. Perkins BA, Ficociello LH, OstranDer BE, et al. Microalbuminuria and the risk for early progressive renal function Decline in type 1 diabetes. J Am Soc Nephrol 2007; 18:1353-1361. (Pubitemid 46536923)
44. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl 1):S11-S66.
45. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disea se: improving global outcomes 2012 clinical practice guiDeline. Ann Int Med 2013; 158:825-830.
46. Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in Type 1 Di abetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005; 54:2164-2171. (Pubitemid 40911280)
47. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20-29.
48. Schwartz GJ, Munoz A, SchneiDer MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629-637.
49. Krolewski AS, Warram JH, Forsblom C, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care 2012; 35:2311-2316. CKD staging by eGFRCYSTATIN C improved ESRD risk stratification based on eGFRCREATININE.
50. Bjornstad P, McQuee n RB, Snell-Bergeon JK. Fasting blood glucose-A missing variable in GFR-estimating equations in type 1 diabetes? PloS one 2013; 9:e96264.
51. Cherney DZ, Sochett EB, Dekker MG, Perkins BA. A bility of cystatin C to Detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes. Diabet Med 2010; 27:1358-1365.
52. Maahs DM, OgDen LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007; 56:2774-2779. (Pubitemid 350044921)
53. Premaratne E, MacIsaac RJ, Finch S, et al. Serial measurements of cystatin C are more accurate than creatinine-based methods in Detecting Declining renal function in type 1 diabetes. Diabetes Care 2008; 31:971-973.
54. Skupien J,WarramJH,Groo pPH, Krolewski AS.Cystatin-baseDestimatedGFR versus creatinine-based and creatinine-and cystatin-based estimated GFR for ESRD and mortality risk in diabetes. Am J Kidney Dis 2013; 62:184-186.
55. Shlipak MG , Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in Determining risk based on kidney function. N Engl J Med 2013; 369:932-943.
56. Maahs DM, Jalal D, McFann K, et al. Systematic shifts in cystatin C between 2006 and 2010. Clin J Am Soc Nephrol 2011; 6:1952-1955.
57. Maahs DM, Prentice N, McFa nn K, et al. Age and sex influence cystatin C in adolescents with and without type 1 diabetes. Diabetes Care 2011; 34:2360-2362.
58. KDOQI. KDOQI Clinical Practice GuiDelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl 2):S12-S154.
59. Maahs D. Early Detection of kidney disease in type 1 diabetes: what do we really know? Diabetes Technol Ther 2012; 14:541-544.
60. Niculescu-Duvaz I, D'Mello L, Maan Z, et al. Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epiDemiological studies. Kidn ey Int 2006; 69:1272-1275.
61. Mafham MM, Niculescu-Duvaz I, Barron J, et al. A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. Ne phr Clin Pract 2007; 106:c104-c112. (Pubitemid 47016328)
62. Groop PH,Thomas MC,Moran JL,et al, The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes,Diabetes,2009,58. 1651-1658.
63. Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013; 369:2459.
64. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7:230-240. (Pubitemid 43286453)
65. von Zur Muhlen C, Schiffer E, Zuerbig P, et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009; 8:335-345.
66. Meier M, Kaiser T, Herrmann A, et al. IDentification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complicat 2005; 19:223-232. (Pubitemid 40910204)
67. Zimmerli LU, Schiffer E, Zurbig P, et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2008; 7:290-298. (Pubitemid 351298443)
68. Snell-Bergeon JK, Maahs DM, O gDen LG, et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009; 11:1-9.
69. Cherney DZ, Scholey JW, Sochett E, et al. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2011; 34:177-180.
70. Har R, Scholey JW, Daneman D, et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 2013; 56: 1166-1173.
71. Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for Development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58:1668-1 671.
72. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33:1337-1343.
73. Cleland SJ, Fisher BM, Colhoun HM, et al. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks' Diabetologia 2013; 56:1462-1470.
74. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further eviDence from the Pittsburgh EpiDemiology of Diabet es Complication Study. Kidney Int 2002; 62:963-970. (Pubitemid 35316726)
75. Perseghin G, Lattuada G, Danna M, et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol-Endoc Metab 2003; 285:E1174-E1181. (Pubitemid 37464367)
76. Houstis N, Rosen ED, LanDer ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440:944-948.
77. Bjornstad P, Snell-Bergeon JK, McFann K, et al. Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complicat 2014; 28:298-304. Data suggest inDepenDence of serum uric acid and insulin sensitivity in T1D.
78. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503-2515.
79. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Supp 2011; S20-S27.
80. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obe Metab 2009; 11:79-88.
81. Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hy 2010; 19:425-431.
82. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-inDepenDent risk factor for diabetic complications. JAMA 2006; 295:1707-1708.
83. Cherney DZ,Reich HN,Scholey JW,et al, The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes,Diabetologia,2013,56,2308-2317.
84. Torres VE. Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int 2009; 76:925-928.
85. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hy 2010; 19:499-504.
86. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-Deficient Brattleboro rats. Proc Natl Acad Sci USA 1999; 96:10397-10402. (Pubitemid 29422569)
87. Gellai M, Silverstein JH, Hwang JC, et al. Influence of vasopressin on renal hemodynamics in conscious Brattleboro rats. Am J Physiol 1984; 246 (6 Pt 2): F819-F827. (Pubitemid 14075692)
88. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258 (4 Pt 2):F973-F979. (Pubitemid 20155510)
89. Strippoli GF, Craig JC, Rochtchina E, et al. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 2011; 16:326-334.